"All babies in the UK will soon have a potentially life-saving vaccine against meningitis B," The Guardian reports. The vaccine, Bexsero, will soon be offered to babies once they reach the age of two months, followed by two more booster shots.
Meningitis B is a highly aggressive strain of bacterial meningitis that infects the protective membranes surrounding the brain and spinal cord. It is very serious and should be treated as a medical emergency. If the infection is left untreated, it can cause severe brain damage and infect the blood (septicaemia). In some cases, bacterial meningitis can be fatal.
The charity Meningitis Now estimates that there are 1,870 cases of meningitis B each year in the UK. Meningitis B is most common in children under five years old, particularly in babies under the age of one.
Initial signs and symptoms of meningitis B in babies include:
For more information, read about the signs and symptoms of serious illness in babies.
The development of a safe and effective meningitis B vaccine is the culmination of more than 20 years of research and represents a significant breakthrough in disease prevention.
The vaccine, Bexsero, is thought to provide 73% protection against meningitis B, which should significantly reduce the number of cases. The vaccine can be administered to infants aged two months or older either by itself, or in combination with other childhood vaccines.
The vaccine has been tested in clinical trials involving more than 8,000 people.
In infants, it was found to have similar levels of safety and tolerability as other routine childhood vaccines. The most commonly reported side effects were:
It is thought that the vaccine will become available on the NHS in the autumn.